10x Genomics Inc. (TXG)

The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the po...

Toronto, Ontario--(Newsfile Corp. - May 26, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces that an amendment to the Company's restricted share unit plan (the "RSU Pl...

Gene sequencing technology company 10x Genomics (TXG 2.52%) hasn't been having it easy in the past few days on the stock market. A bearish analyst move dampened sentiment on the company, and according...

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Results continue to indicate high-grade mineralization and the long-term potential of the deposit (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - Ma...

The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the po...

10x Genomics, Inc. (NASDAQ:TXG ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Cassie Corneau – Senior Director, Investor Relations Serge Saxonov – Chief Executive Offic...

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Str...

10x Genomics (TXG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.50 per share a year ago.

Results in line with expectations and tracking well to full-year guidance (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - May 7, 2025) - Torex Gold ...